Complement activation as a biomarker for Alzheimer's disease

Immunobiology

Volumn 217, Issue 2, 2012, Pages 204-215

  Aiyaz, Mohammed ^a   Lupton, Michelle K ^a   Proitsi, Petroula ^a   Powell, John F ^a   Lovestone, Simon ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; Biomarker; Blood; Complement; Genetic risk factors; Inflammation; Plasma

Indexed keywords

ALPHA 2 MACROGLOBULIN; AMYLOID; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; BRAIN PROTEIN; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; CLUSTERIN; COMPLEMENT; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C4B; INTERLEUKIN 1; INTERLEUKIN 6; ROSIGLITAZONE; TAU PROTEIN;

ALZHEIMER DISEASE; AMYLOID PLAQUE; BRAIN LEVEL; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT SYSTEM; DIAGNOSTIC ACCURACY; DISEASE COURSE; DISEASE MARKER; DISEASE PREDISPOSITION; DRUG EFFICACY; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC MARKER; HUMAN; INFLAMMATION; INNATE IMMUNITY; PATHOGENESIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN AGGREGATION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN POLYMORPHISM; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE;

ALZHEIMER DISEASE; AMYLOID; BIOLOGICAL MARKERS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; HUMANS; MACULAR DEGENERATION; PLAQUE, AMYLOID;

EID: 84855260469     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2011.07.023     Document Type: Review

References (158)

1. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., Cooper N.R., Eikelenboom P., Emmerling M., Fiebich B.L., Finch C.E., Frautschy S., Griffin W.S., Hampel H., Hull M., Landreth G., Lue L., Mrak R., Mackenzie I.R., McGeer P.L., O'Banion M.K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., Van Muiswinkel F.L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol. Aging 2000, 21:383-421.
2. Akuffo E.L., Davis J.B., Fox S.M., Gloger I.S., Hosford D., Kinsey E.E., Jones N.A., Nock C.M., Roses A.D., Saunders A.M., Skehel J.M., Smith M.A., Cutler P. The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimer's disease patients responding to treatment with rosiglitazone. Biomarkers 2008, 13:618-636.
3. Andersen K., Launer L.J., Ott A., Hoes A.W., Breteler M.M., Hofman A. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study. Neurology 1995, 45:1441-1445.
4. Anderson D.H., Mullins R.F., Hageman G.S., Johnson L.V. A role for local inflammation in the formation of drusen in the aging eye. Am. J. Ophthalmol. 2002, 134:411-431.
5. Annunziata P., Maimone D., Guazzi G.C. Association of polyclonal anti-GM1 IgM and anti-neurofilament antibodies with CSF oligoclonal bands in a young with amyotrophic lateral sclerosis. Acta Neurol. Scand. 1995, 92:387-393.
6. Atkinson A.J., Colburn W.A., DeGruttola V.G., DeMets D.L., Downing G.J., Hoth D.F., Oates J.A., Peck C.C., Schooley R.T., Spiker B.A., Woodcock J., Zeger S.L. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001, 69:89-95.
7. Ballard C.G., Bannister C. Criteria in the Diagnosis of Dementia 2005, 24-25. Dementia, London: Hodder. A. Burns, J. O'Brien, D. Ames (Eds.).
8. Bass M.P., Yamaoka L.H., Scott W.K., Gaskell P.C., Welsh-Bohmer K.A., Roses A.D., Saunders A.M., Haines J.L., Pericak-Vance M.A. No association of alpha1-antichymotrypsin flanking region polymorphism and Alzheimer disease risk in early- and late-onset Alzheimer disease patients. Neurosci. Lett. 1998, 250:79-82.
9. Bauer J., Strauss S., Schreiter-Gasser U., Ganter U., Schlegel P., Witt I., Yolk B., Berger M. Interleukin-6 and [alpha]-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett. 1991, 285:111-114.
10. Belbin O., Dunn J.L., Chappell S., Ritchie A.E., Ling Y., Morgan L., Pritchard A., Warden D.R., Lendon C.L., Lehmann D.J., Mann D.M., Smith A.D., Kalsheker N., Morgan K. A SNP in the ACT gene associated with astrocytosis and rapid cognitive decline in AD. Neurobiol. Aging 2008, 29:1167-1176.
11. Benoit M.E., Tenner A.J. Complement protein C1q-mediated neuroprotection is correlated with regulation of neuronal gene and microRNA expression. J. Neurosci. 2011, 31:3459-3469.
12. Bertram L., McQueen M.B., Mullin K., Blacker D., Tanzi R.E. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat. Genet. 2007, 39:17-23.
13. Biffi A., Anderson C.D., Desikan R.S., Sabuncu M., Cortellini L., Schmansky N., Salat D., Rosand J. Genetic variation and neuroimaging measures in Alzheimer disease. Arch. Neurol. 2010, 67:677-685.
14. Blennow K. CSF biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug treatment. Expert. Rev. Mol. Diagn. 2005, 5:661-672.
15. Blennow K., Hampel H., Weiner M., Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 2010, 6:131-144.
16. Brouwers N., Van C.C., Engelborghs S., Lambert J.C., Bettens K., Le B.N., Pasquier F., Montoya A.G., Peeters K., Mattheijssens M., Vandenberghe R., De Deyn P.P., Cruts M., Amouyel P., Sleegers K., Van B.C. Alzheimer risk associated with a copy number variation in the complement receptor 1 increasing C3b/C4b binding sites. Mol. Psychiatry 2011, (March). [Epub ahead of print].
17. Carrasquillo M.M., Belbin O., Hunter T.A., Ma L., Bisceglio G.D., Zou F., Crook J.E., Pankratz V.S., Dickson D.W., Graff-Radford N.R., Petersen R.C., Morgan K., Younkin S.G. Replication of CLU. CR1, and PICALM associations with Alzheimer disease. Arch. Neurol. 2010, 67:961-964.
18. Chibnik L.B., Shulman J.M., Leurgans S.E., Schneider J.A., Wilson R.S., Tran D., Aubin C., Buchman A.S., Heward C.B., Myers A.J., Hardy J.A., Huentelman M.J., Corneveaux J.J., Reiman E.M., Evans D.A., Bennett D.A., De Jager P.L. CR1 is associated with amyloid plaque burden and age-related cognitive decline. Ann. Neurol. 2011, 69:560-569.
19. Choi M., Scholl U.I., Ji W., Liu T., Tikhonova I.R., Zumbo P., Nayir A., Bakkaloglu A., Ozen S., Sanjad S., Nelson-Williams C., Farhi A., Mane S., Lifton R.P. Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:19096-19101.
20. Clarimon J., Bertranpetit J., Calafell F., Boada M., Tarraga L., Comas D. Joint analysis of candidate genes related to Alzheimer's disease in a Spanish population. Psychiatr. Genet. 2003, 13:85-90.
21. Conejero-Goldberg C., Hyde T.M., Chen S., Dreses-Werringloer U., Herman M.M., Kleinman J.E., Davies P., Goldberg T.E. Molecular signatures in post-mortem brain tissue of younger individuals at high risk for Alzheimer's disease as based on APOE genotype. Mol. Psychiatry 2010, (May). (Epub ahead of print).
22. Corneveaux J.J., Myers A.J., Allen A.N., Pruzin J.J., Ramirez M., Engel A., Nalls M.A., Chen K., Lee W., Chewning K., Villa S.E., Meechoovet H.B., Gerber J.D., Frost D., Benson H.L., O'Reilly S., Chibnik L.B., Shulman J.M., Singleton A.B., Craig D.W., Van Keuren-Jensen K.R., Dunckley T., Bennett D.A., De Jager P.L., Heward C., Hardy J., Reiman E.M., Huentelman M.J. Association of CR1. CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals. Hum. Mol. Genet. 2010, 19:3295-3301.
23. Crehan H., Holton P., Wray S., Pocock J., Guerreiro R., Hardy J. Complement Receptor 1 (CR1) and Alzheimer's Disease. Immunobiology 2012, 217:244-250.
24. Cutler P., Akuffo E.L., Bodnar W.M., Briggs D.M., Davis J.B., Debouck C.M., Fox S.M., Gibson R.A., Gormley D.A., Holbrook J.D., Hunter A.J., Kinsey E.E., Prinjha R., Richardson J.C., Roses A.D., Smith M.A., Tsokanas N., Wille D.R., Wu W., Yates J.W., Gloger I.S. Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium-derived factor: two novel biomarkers of Alzheimer's disease in human plasma. Proteomics Clin. Appl. 2008, 2:467-477.
25. de Leon M.J., DeSanti S., Zinkowski R., Mehta P.D., Pratico D., Segal S., Clark C., Kerkman D., DeBernardis J., Li J., Lair L., Reisberg B., Tsui W., Rusinek H. MRI and CSF studies in the early diagnosis of Alzheimer's disease. J. Int. Med. 2004, 256:205-223.
26. Dewan A., Liu M., Hartman S., Zhang S.S., Liu D.T., Zhao C., Tam P.O., Chan W.M., Lam D.S., Snyder M., Barnstable C., Pang C.P., Hoh J. HTRA1 promoter polymorphism in wet age-related macular degeneration. Science 2006, 314:989-992.
27. Didierjean O., Martinez M., Campion D., Hannequin D., Dubois B., Martin C., Puel M., Thomas A.C., Pasquier F., Moreau O., Babron M.C., Penet C., Agid Y., Clerget-Darpoux F., Frebourg T., Brice A. No effect of the alpha1-antichymotrypsin A allele in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 1997, 63:103-105.
28. Dubois B., Feldman H.H., Jacova C., DeKosky S.T., Barberger-Gateau P., Cummings J., Delacourte A., Galasko D., Gauthier S., Jicha G., Meguro K., O'Brien J., Pasquier F., Robert P., Rossor M., Salloway S., Stern Y., Visser P.J., Scheltens P. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007, 6:734-746.
29. Dunkelberger J.R., Song W.C. Complement and its role in innate and adaptive immune responses. Cell Res. 2010, 20:34-50.
30. Durany,N., K. Morgan, J. Thome, L. Tilley, N. Kalsheker, G. Munch, P. Riederer, Cruz-Sanchez, F., 1998. Relationship between á1-antichymotypsin micro-satelletie and apolipoprotein E in Alzheimer's disease, pp. 315-320.
31. Edwards A.O., Ritter R., Abel K.J., Manning A., Panhuysen C., Farrer L.A. Complement factor H polymorphism and age-related macular degeneration. Science 2005, 308:421-424.
32. Egensperger R., Kosel S., Schnopp N.M., Mehraein P., Graeber M.B. Association of the mitochondrial tRNA(A4336G) mutation with Alzheimer's and Parkinson's diseases. Neuropathol. Appl. Neurobiol. 1997, 23:315-321.
33. Emahazion T., Feuk L., Jobs M., Sawyer S.L., Fredman D., St C.D., Prince J.A., Brookes A.J. SNP association studies in Alzheimer's disease highlight problems for complex disease analysis. Trends Genet. 2001, 17:407-413.
34. Engelhart M.J., Geerlings M.I., Meijer J., Kiliaan A., Ruitenberg A., van Swieten J.C., Stijnen T., Hofman A., Witteman J.C.M., Breteler M.M.B. Inflammatory proteins in plasma and the risk of dementia: The Rotterdam Study. Arch Neurol. 2004, 61:668-672.
35. Ezquerra M., Blesa R., Tolosa E., Ballesta F., Oliva R. Alpha-antichymotrypsin gene polymorphism and risk for Alzheimer's disease in the Spanish population. Neurosci. Lett. 1998, 240:107-109.
36. Ferri C.P., Prince M., Brayne C., Brodaty H., Fratiglioni L., Ganguli M., Hall K., Hasegawa K., Hendrie H., Huang Y., Jorm A., Mathers C., Menezes P.R., Rimmer E., Scazufca M. Global prevalence of dementia: a Delphi consensus study. Lancet 2005, 366:2112-2117.
37. Finehout E.J., Franck Z., Lee K.H. Complement protein isoforms in CSF as possible biomarkers for neurodegenerative disease. Dis. Markers 2005, 21:93-101.
38. Flex A., Pola R., Serricchio M., Gaetani E., Proia A.S., Di G.A., Papaleo P., Bernabei R., Pola P. Polymorphisms of the macrophage inhibitory factor and C-reactive protein genes in subjects with Alzheimer's dementia. Dement. Geriatr. Cogn. Disord. 2004, 18:261-264.
39. Fratiglioni L., Launer L.J., Andersen K., Breteler M.M., Copeland J.R., Dartigues J.F., Lobo A., Martinez-Lage J., Soininen H., Hofman A. Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic diseases in the Elderly Research Group. Neurology 2000, 54:S10-S15.
40. Friedman D.S., O'Colmain B.J., Munoz B., Tomany S.C., McCarty C., de Jong P.T., Nemesure B., Mitchell P., Kempen J. Prevalence of age-related macular degeneration in the United States. Arch. Ophthalmol. 2004, 122:564-572.
41. Gatta L.B., Vitali M., Zanola A., Venturelli E., Fenoglio C., Galimberti D., Scarpini E., Finazzi D. Polymorphisms in the LOC387715/ARMS2 putative gene and the risk for Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2008, 26:169-174.
42. Gatz M., Fratiglioni L., Johansson B., Berg S., Mortimer J.A., Reynolds C.A., Fiske A., Pedersen N.L. Complete ascertainment of dementia in the Swedish Twin Registry: the HARMONY study. Neurobiol. Aging 2005, 26:439-447.
43. Gatz M., Reynolds C.A., Fratiglioni L., Johansson B., Mortimer J.A., Berg S., Fiske A., Pedersen N.L. Role of genes and environments for explaining Alzheimer disease. Arch Gen. Psychiatry 2006, 63:168-174.
44. Gelissen I.C., Hochgrebe T., Wilson M.R., Easterbrook-Smith S.B., Jessup W., Dean R.T., Brown A.J. Apolipoprotein J (clusterin) induces cholesterol export from macrophage-foam cells: a potential anti-atherogenic function?. Biochem. J. 1998, 331(Pt 1):231-237.
45. Giannakopoulos P., Kovari E., French L.E., Viard I., Hof P.R., Bouras C. Possible neuroprotective role of clusterin in Alzheimer's disease: a quantitative immunocytochemical study. Acta Neuropathol. 1998, 95:387-394.
46. Giedraitis V., Kilander L., german-Gunnarsson M., Sundelof J., Axelsson T., Syvanen A.C., Lannfelt L., Glaser A. Genetic analysis of Alzheimer's disease in the Uppsala Longitudinal Study of Adult Men. Dement. Geriatr. Cogn. Disord. 2009, 27:59-68.
47. Giometto B., Argentiero V., Sanson F., Ongaro G., Tavolato B. Acute-phase proteins in Alzheimer's disease. Eur. Neurol. 1988, 28:30-33.
48. Gold B., Merriam J.E., Zernant J., Hancox L.S., Taiber A.J., Gehrs K., Cramer K., Neel J., Bergeron J., Barile G.R., Smith R.T., Hageman G.S., Dean M., Allikmets R. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat. Genet. 2006, 38:458-462.
49. Grewal R.P., Morgan T.E., Finch C.E. C1qB and clusterin mRNA increase in association with neurodegeneration in sporadic amyotrophic lateral sclerosis. Neurosci. Lett. 1999, 271:65-67.
50. Guerreiro R.J., Beck J., Gibbs J.R., Santana I., Rossor M.N., Schott J.M., Nalls M.A., Ribeiro H., Santiago B., Fox N.C., Oliveira C., Collinge J., Mead S., Singleton A., Hardy J. Genetic variability in CLU and its association with Alzheimer's disease. PLoS One 2010, 5:e9510.
51. Hageman G.S., Luthert P.J., Victor Chong N.H., Johnson L.V., Anderson D.H., Mullins R.F. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog. Retin. Eye Res. 2001, 20:705-732.
52. Haines J.L., Hauser M.A., Schmidt S., Scott W.K., Olson L.M., Gallins P., Spencer K.L., Kwan S.Y., Noureddine M., Gilbert J.R., Schnetz-Boutaud N., Agarwal A., Postel E.A., Pericak-Vance M.A. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005, 308:419-421.
53. Hamilton G., Proitsi P., Williams J., O'Donovan M., Owen M., Powell J., Lovestone S. Complement factor H Y402H polymorphism is not associated with late-onset Alzheimer's disease. Neuromol. Med. 2007, 9:331-334.
54. Harold D., Abraham R., Hollingworth P., Sims R., Gerrish A., Hamshere M.L., Pahwa J.S., Moskvina V., Dowzell K., Williams A., Jones N., Thomas C., Stretton A., Morgan A.R., Lovestone S., Powell J., Proitsi P., Lupton M.K., Brayne C., Rubinsztein D.C., Gill M., Lawlor B., Lynch A., Morgan K., Brown K.S., Passmore P.A., Craig D., McGuinness B., Todd S., Holmes C., Mann D., Smith A.D., Love S., Kehoe P.G., Hardy J., Mead S., Fox N., Rossor M., Collinge J., Maier W., Jessen F., Schurmann B., van den B.H., Heuser I., Kornhuber J., Wiltfang J., Dichgans M., Frolich L., Hampel H., Hull M., Rujescu D., Goate A.M., Kauwe J.S., Cruchaga C., Nowotny P., Morris J.C., Mayo K., Sleegers K., Bettens K., Engelborghs S., De Deyn P.P., Van B.C., Livingston G., Bass N.J., Gurling H., McQuillin A., Gwilliam R., Deloukas P., Al-Chalabi A., Shaw C.E., Tsolaki M., Singleton A.B., Guerreiro R., Muhleisen T.W., Nothen M.M., Moebus S., Jockel K.H., Klopp N., Wichmann H.E., Carrasquillo M.M., Pankratz V.S., Younkin S.G., Holmans P.A., O'Donovan M., Owen M.J., Williams J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet. 2009, 41(10):1088-1093.
55. Hayden K.M., Zandi P.P., Khachaturian A.S., Szekely C.A., Fotuhi M., Norton M.C., Tschanz J.T., Pieper C.F., Corcoran C., Lyketsos C.G., Breitner J.C., Welsh-Bohmer K.A. Does NSAID use modify cognitive trajectories in the elderly? The Cache County study. Neurology 2007, 69:275-282.
56. Hecker L.A., Edwards A.O., Ryu E., Tosakulwong N., Baratz K.H., Brown W.L., Charbel I.P., Scholl H.P., Pollok-Kopp B., Schmid-Kubista K.E., Bailey K.R., Oppermann M. Genetic control of the alternative pathway of complement in humans and age-related macular degeneration. Hum. Mol. Genet. 2010, 19:209-215.
57. Helisalmi S., Mannermaa A., Lehtovirta M., Ryynanen M., Riekkinen P., Soininen H. No association between alpha1-antichymotrypsin polymorphism, apolipoprotein E and patients with late-onset Alzheimer's disease. Neurosci. Lett. 1997, 231:56-58.
58. Hollingworth P., Harold D., Jones L., Owen M.J., Williams J. Alzheimer's disease genetics: current knowledge and future challenges. Int. J. Geriatr. Psychiatry 2010, (October). (Epub ahead of print).
59. Hollingworth P., Harold D., Sims R., Gerrish A., Lambert J.C., Carrasquillo M.M., Abraham R., Hamshere M.L., Pahwa J.S., Moskvina V., Dowzell K., Jones N., Stretton A., Thomas C., Richards A., Ivanov D., Widdowson C., Chapman J., Lovestone S., Powell J., Proitsi P., Lupton M.K., Brayne C., Rubinsztein D.C., Gill M., Lawlor B., Lynch A., Brown K.S., Passmore P.A., Craig D., McGuinness B., Todd S., Holmes C., Mann D., Smith A.D., Beaumont H., Warden D., Wilcock G., Love S., Kehoe P.G., Hooper N.M., Vardy E.R., Hardy J., Mead S., Fox N.C., Rossor M., Collinge J., Maier W., Jessen F., Ruther E., Schurmann B., Heun R., Kolsch H., van den B.H., Heuser I., Kornhuber J., Wiltfang J., Dichgans M., Frolich L., Hampel H., Gallacher J., Hull M., Rujescu D., Giegling I., Goate A.M., Kauwe J.S., Cruchaga C., Nowotny P., Morris J.C., Mayo K., Sleegers K., Bettens K., Engelborghs S., De Deyn P.P., Van B.C., Livingston G., Bass N.J., Gurling H., McQuillin A., Gwilliam R., Deloukas P., Al-Chalabi A., Shaw C.E., Tsolaki M., Singleton A.B., Guerreiro R., Muhleisen T.W., Nothen M.M., Moebus S., Jockel K.H., Klopp N., Wichmann H.E., Pankratz V.S., Sando S.B., Aasly J.O., Barcikowska M., Wszolek Z.K., Dickson D.W., Graff-Radford N.R., Petersen R.C., van Duijn C.M., Breteler M.M., Ikram M.A., DeStefano A.L., Fitzpatrick A.L., Lopez O., Launer L.J., Seshadri S., Berr C., Campion D., Epelbaum J., Dartigues J.F., Tzourio C., Alperovitch A., Lathrop M., Feulner T.M., Friedrich P., Riehle C., Krawczak M., Schreiber S., Mayhaus M., Nicolhaus S., Wagenpfeil S., Steinberg S., Stefansson H., Stefansson K., Snaedal J., Bjornsson S., Jonsson P.V., Chouraki V., Genier-Boley B., Hiltunen M., Soininen H., Combarros O., Zelenika D., Delepine M., Bullido M.J., Pasquier F., Mateo I., Frank-Garcia A., Porcellini E., Hanon O., Coto E., Alvarez V., Bosco P., Siciliano G., Mancuso M., Panza F., Solfrizzi V., Nacmias B., Sorbi S., Bossu P., Piccardi P., Arosio B., Annoni G., Seripa D., Pilotto A., Scarpini E., Galimberti D., Brice A., Hannequin D., Licastro F., Jones L., Holmans P.A., Jonsson T., Riemenschneider M., Morgan K., Younkin S.G., Owen M.J., O'Donovan M., Amouyel P., Williams J. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1. CD33 and CD2AP are associated with Alzheimer's disease. Nat. Genet. 2011, 43(5):429-435.
60. Hong T., Tan A.G., Mitchell P., Wang J.J. A Review and meta-analysis of the association between C-reactive protein and age-related macular degeneration. Surv. Ophthalmol. 2011, 56:184-194.
61. Hourcade D.E., Mitchell L., Kuttner-Kondo L.A., Atkinson J.P., Medof M.E. Decay-accelerating factor (DAF), complement receptor 1 (CR1), and factor H dissociate the complement AP C3 convertase (C3bBb) via sites on the type A domain of Bb. J. Biol. Chem. 2002, 277:1107-1112.
62. Hye A., Lynham S., Thambisetty M., Causevic M., Campbell J., Byers H.L., Hooper C., Rijsdijk F., Tabrizi S.J., Banner S., Shaw C.E., Foy C., Poppe M., Archer N., Hamilton G., Powell J., Brown R.G., Sham P., Ward M., Lovestone S. Proteome-based plasma biomarkers for Alzheimer's disease. Brain 2006, 129:3042-3050.
63. Itabashi S., Arai H., Matsui T., Matsushita S., Muramatsu T., Higuchi S., Trojanowski J.Q., Sasaki H. Absence of association of alpha1-antichymotrypsin polymorphisms with Alzheimer's disease: a report on autopsy-confirmed cases. Exp. Neurol. 1998, 151:237-240.
64. Jack C.R., Dickson D.W., Parisi J.E., Xu Y.C., Cha R.H., O'Brien P.C., Edland S.D., Smith G.E., Boeve B.F., Tangalos E.G., Kokmen E., Petersen R.C. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology 2002, 58:750-757.
65. Jakobsdottir J., Conley Y.P., Weeks D.E., Ferrell R.E., Gorin M.B. C2 and CFB genes in age-related maculopathy and joint action with CFH and LOC387715 genes. PLoS One 2008, 3:e2199.
66. Jakobsdottir J., Conley Y.P., Weeks D.E., Mah T.S., Ferrell R.E., Gorin M.B. Susceptibility genes for age-related maculopathy on chromosome 10q26. Am. J. Hum. Genet. 2005, 77:389-407.
67. Jehle A.W., Gardai S.J., Li S., Linsel-Nitschke P., Morimoto K., Janssen W.J., Vandivier R.W., Wang N., Greenberg S., Dale B.M., Qin C., Henson P.M., Tall A.R. ATP-binding cassette transporter A7 enhances phagocytosis of apoptotic cells and associated ERK signaling in macrophages. J. Cell Biol. 2006, 174:547-556.
68. Johnson L.V., Leitner W.P., Staples M.K., Anderson D.H. Complement activation and inflammatory processes in Drusen formation and age related macular degeneration. Exp. Eye Res. 2001, 73:887-896.
69. Johnson L.V., Ozaki S., Staples M.K., Erickson P.A., Anderson D.H. A potential role for immune complex pathogenesis in drusen formation. Exp. Eye Res. 2000, 70:441-449.
70. Jones L., Holmans P.A., Hamshere M.L., Harold D., Moskvina V., Ivanov D., Pocklington A., Abraham R., Hollingworth P., Sims R., Gerrish A., Pahwa J.S., Jones N., Stretton A., Morgan A.R., Lovestone S., Powell J., Proitsi P., Lupton M.K., Brayne C., Rubinsztein D.C., Gill M., Lawlor B., Lynch A., Morgan K., Brown K.S., Passmore P.A., Craig D., McGuinness B., Todd S., Holmes C., Mann D., Smith A.D., Love S., Kehoe P.G., Mead S., Fox N., Rossor M., Collinge J., Maier W., Jessen F., Schurmann B., van den B.H., Heuser I., Peters O., Kornhuber J., Wiltfang J., Dichgans M., Frolich L., Hampel H., Hull M., Rujescu D., Goate A.M., Kauwe J.S., Cruchaga C., Nowotny P., Morris J.C., Mayo K., Livingston G., Bass N.J., Gurling H., McQuillin A., Gwilliam R., Deloukas P., Al-Chalabi A., Shaw C.E., Singleton A.B., Guerreiro R., Muhleisen T.W., Nothen M.M., Moebus S., Jockel K.H., Klopp N., Wichmann H.E., Ruther E., Carrasquillo M.M., Pankratz V.S., Younkin S.G., Hardy J., O'Donovan M.C., Owen M.J., Williams J. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One 2010, 5:e13950.
71. Jongen P.J., Doesburg W.H., Ibrahim-Stappers J.L., Lemmens W.A., Hommes O.R., Lamers K.J. Cerebrospinal fluid C3 and C4 indexes in immunological disorders of the central nervous system. Acta Neurol. Scand. 2000, 101:116-121.
72. Jun G., Naj A.C., Beecham G.W., Wang L.S., Buros J., Gallins P.J., Buxbaum J.D., Ertekin-Taner N., Fallin M.D., Friedland R., Inzelberg R., Kramer P., Rogaeva E., St George-Hyslop P., Cantwell L.B., Dombroski B.A., Saykin A.J., Reiman E.M., Bennett D.A., Morris J.C., Lunetta K.L., Martin E.R., Montine T.J., Goate A.M., Blacker D., Tsuang D.W., Beekly D., Cupples L.A., Hakonarson H., Kukull W., Foroud T.M., Haines J., Mayeux R., Farrer L.A., Pericak-Vance M.A., Schellenberg G.D. Meta-analysis confirms CR1 CLU, and PICALM as Alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch. Neurol. 2010, 67:1473-1484.
73. Kamboh M.I., Minster R.L., Demirci F.Y., Ganguli M., DeKosky S.T., Lopez O.L., Barmada M.M. Association of CLU and PICALM variants with Alzheimer's disease. Neurobiol. Aging 2010, (June). (Epub ahead of print).
74. Kamboh M.I., Sanghera D.K., Ferrell R.E., DeKosky S.T. APOE*4-associated Alzheimer's disease risk is modified by alpha 1-antichymotrypsin polymorphism. Nat. Genet. 1995, 10:486-488.
75. Kanda A., Chen W., Othman M., Branham K.E., Brooks M., Khanna R., He S., Lyons R., Abecasis G.R., Swaroop A. A variant of mitochondrial protein LOC387715/ARMS2, not HTRA1, is strongly associated with age-related macular degeneration. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:16227-16232.
76. Katta S., Kaur I., Chakrabarti S. The molecular genetic basis of age-related macular degeneration: an overview. J. Genet. 2009, 88:425-449.
77. Khera R., Das N. Complement Receptor 1: disease associations and therapeutic implications. Mol. Immunol. 2009, 46:761-772.
78. Klein R.J., Zeiss C., Chew E.Y., Tsai J.Y., Sackler R.S., Haynes C., Henning A.K., SanGiovanni J.P., Mane S.M., Mayne S.T., Bracken M.B., Ferris F.L., Ott J., Barnstable C., Hoh J. Complement factor H polymorphism in age-related macular degeneration. Science 2005, 308:385-389.
79. Lamb H., Christie J., Singleton A.B., Leake A., Perry R.H., Ince P.G., McKeith I.G., Melton L.M., Edwardson J.A., Morris C.M. Apolipoprotein E and alpha-1 antichymotrypsin polymorphism genotyping in Alzheimer's disease and in dementia with Lewy bodies distinctions between diseases. Neurology 1998, 50:388-391.
80. Lambert J.C., Heath S., Even G., Campion D., Sleegers K., Hiltunen M., Combarros O., Zelenika D., Bullido M.J., Tavernier B., Letenneur L., Bettens K., Berr C., Pasquier F., Fievet N., Barberger-Gateau P., Engelborghs S., De D.P., Mateo I., Franck A., Helisalmi S., Porcellini E., Hanon O., de Pancorbo M.M., Lendon C., Dufouil C., Jaillard C., Leveillard T., Alvarez V., Bosco P., Mancuso M., Panza F., Nacmias B., Bossu P., Piccardi P., Annoni G., Seripa D., Galimberti D., Hannequin D., Licastro F., Soininen H., Ritchie K., Blanche H., Dartigues J.F., Tzourio C., Gut I., Van B.C., Alperovitch A., Lathrop M., Amouyel P. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet. 2009, 41:1094-1099.
81. Le F.I., Laumet G., Richard F., Fievet N., Berr C., Rouaud O., Delcourt C., Amouyel P., Lambert J.C. Association study of the CFH Y402H polymorphism with Alzheimer's disease. Neurobiol. Aging 2010, 31:165-166.
82. Li B., Leal S.M. Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data. Am. J. Hum. Genet. 2008, 83:311-321.
83. Li H., Wetten S., Li L., St Jean P.L., Upmanyu R., Surh L., Hosford D., Barnes M.R., Briley J.D., Borrie M., Coletta N., Delisle R., Dhalla D., Ehm M.G., Feldman H.H., Fornazzari L., Gauthier S., Goodgame N., Guzman D., Hammond S., Hollingworth P., Hsiung G.Y., Johnson J., Kelly D.D., Keren R., Kertesz A., King K.S., Lovestone S., Loy-English I., Matthews P.M., Owen M.J., Plumpton M., Pryse-Phillips W., Prinjha R.K., Richardson J.C., Saunders A., Slater A.J., St George-Hyslop P.H., Stinnett S.W., Swartz J.E., Taylor R.L., Wherrett J., Williams J., Yarnall D.P., Gibson R.A., Irizarry M.C., Middleton L.T., Roses A.D. Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch. Neurol. 2008, 65:45-53.
84. Li Y., Liu L., Barger S.W., Griffin W.S. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J. Neurosci. 2003, 23:1605-1611.
85. Licastro F., Chiappelli M., Grimaldi L.M., Morgan K., Kalsheker N., Calabrese E., Ritchie A., Porcellini E., Salani G., Franceschi M., Canal N. A new promoter polymorphism in the alpha-1-antichymotrypsin gene is a disease modifier of Alzheimer's disease. Neurobiol. Aging 2005, 26:449-453.
86. Licastro F., Pedrini S., Caputo L., Annoni G., Davis L.J., Ferri C., Casadei V., Grimaldi L.M.E. Increased plasma levels of interleukin-1, interleukin-6 and [alpha]-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain?. J. Neuroimmunol. 2000, 103:97-102.
87. Liew C.C., Ma J., Tang H.C., Zheng R., Dempsey A.A. The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. J. Lab. Clin. Med. 2006, 147:126-132.
88. Liu D.J., Leal S.M. A novel adaptive method for the analysis of next-generation sequencing data to detect complex trait associations with rare variants due to gene main effects and interactions. PLoS Genet. 2010, 6:e1001156.
89. Loeffler D.A., Camp D.M., Bennett D.A. Plaque complement activation and cognitive loss in Alzheimer's disease. J. Neuroinflamm. 2008, 5:9.
90. Lovestone S., Francis P., Kloszewska I., Mecocci P., Simmons A., Soininen H., Spenger C., Tsolaki M., Vellas B., Wahlund L.O., Ward M. AddNeuroMed - the European collaboration for the discovery of novel biomarkers for Alzheimer's disease. Ann. N.Y. Acad. Sci. 2009, 1180:36-46.
91. Luedecking-Zimmer E., DeKosky S.T., Nebes R., Kamboh M.I. Association of the 3' UTR transcription factor LBP-1c/CP2/LSF polymorphism with late-onset Alzheimer's disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2003, 117B:114-117.
92. Lupton M.K., Proitsi P., Danillidou M., Tsolaki M., Hamilton G., Wroe R., Pritchard M., Lord K., Martin B.M., Kloszewska I., Soininen H., Mecocci P., Vellas B., Harold D., Hollingworth P., Lovestone S., Powell J.F. Deep sequencing of the nicastrin gene in pooled DNA, the identification of genetic variants that affect risk of Alzheimer's disease. PLoS One 2011, 6:e17298.
93. Maes O.C., Xu S., Yu B., Chertkow H.M., Wang E., Schipper H.M. Transcriptional profiling of Alzheimer blood mononuclear cells by microarray. Neurobiol. Aging 2007, 28:1795-1809.
94. Maher B. Personal genomes: the case of the missing heritability. Nature 2008, 456:18-21.
95. Maller J., George S., Purcell S., Fagerness J., Altshuler D., Daly M.J., Seddon J.M. Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration. Nat. Genet. 2006, 38:1055-1059.
96. Maller J.B., Fagerness J.A., Reynolds R.C., Neale B.M., Daly M.J., Seddon J.M. Variation in complement factor 3 is associated with risk of age-related macular degeneration. Nat. Genet. 2007, 39:1200-1201.
97. Marksteiner J., Hinterhuber H., Humpel C. Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein. Drugs Today (Barc.) 2007, 43:423-431.
98. McIlroy S.P., Vahidassr M.D., Savage D.A., Lloyd F., Patterson C.C., Lawson J.T., Passmore A.P. Association of serum AACT levels and AACT signal polymorphism with late-onset Alzheimer's disease in Northern Ireland. Int. J. Geriatr. Psychiatry 2000, 15:260-266.
99. Morgan K., Morgan L., Carpenter K., Lowe J., Lam L., Cave S., Xuereb J., Wischik C., Harrington C., Kalsheker N.A. Microsatellite polymorphism of the alpha 1-antichymotrypsin gene locus associated with sporadic Alzheimer's disease. Hum. Genet. 1997, 99:27-31.
100. Morimoto K., Horio J., Satoh H., Sue L., Beach T., Arita S., Tooyama I., Konishi Y. Expression profiles of cytokines in the brains of Alzheimer's Disease (AD) patients compared to the brains of non-demented patients with and without increasing ad pathology. J. Alzheimers. Dis. 2011, 2(March). (Epub ahead of print).
101. Mueller S.G., Weiner M.W., Thal L.J., Petersen R.C., Jack C.R., Jagust W., Trojanowski J.Q., Toga A.W., Beckett L. Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement. 2005, 1:55-66.
102. Muller U., Bodeker R.H., Gerundt I., Kurz A. Lack of association between alpha 1-antichymotrypsin polymorphism. Alzheimer's disease, and allele epsilon 4 of apolipoprotein E. Neurology 1996, 47:1575-1577.
103. Myers A.J., Marshall H., Holmans P., Compton D., Crook R.J., Mander A.P., Nowotny P., Smemo S., Dunstan M., Jehu L., Wang J.C., Hamshere M., Morris J.C., Norton J., Chakraventy S., Tunstall N., Lovestone S., Petersen R., O'Donovan M., Jones L., Williams J., Owen M.J., Hardy J., Goate A. Variation in the urokinase-plasminogen activator gene does not explain the chromosome 10 linkage signal for late onset AD. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2004, 124B:29-37.
104. Nacmias B., Tedde A., Latorraca S., Piacentini S., Bracco L., Amaducci L., Guarnieri B.M., Petruzzi C., Ortenzi L., Sorbi S. Apolipoprotein E and alpha1-antichymotrypsin polymorphism in Alzheimer's disease. Ann. Neurol. 1996, 40:678-680.
105. Naj A.C., Jun G., Beecham G.W., Wang L.S., Vardarajan B.N., Buros J., Gallins P.J., Buxbaum J.D., Jarvik G.P., Crane P.K., Larson E.B., Bird T.D., Boeve B.F., Graff-Radford N.R., De Jager P.L., Evans D., Schneider J.A., Carrasquillo M.M., Ertekin-Taner N., Younkin S.G., Cruchaga C., Kauwe J.S., Nowotny P., Kramer P., Hardy J., Huentelman M.J., Myers A.J., Barmada M.M., Demirci F.Y., Baldwin C.T., Green R.C., Rogaeva E., George-Hyslop P.S., Arnold S.E., Barber R., Beach T., Bigio E.H., Bowen J.D., Boxer A., Burke J.R., Cairns N.J., Carlson C.S., Carney R.M., Carroll S.L., Chui H.C., Clark D.G., Corneveaux J., Cotman C.W., Cummings J.L., Decarli C., DeKosky S.T., az-Arrastia R., Dick M., Dickson D.W., Ellis W.G., Faber K.M., Fallon K.B., Farlow M.R., Ferris S., Frosch M.P., Galasko D.R., Ganguli M., Gearing M., Geschwind D.H., Ghetti B., Gilbert J.R., Gilman S., Giordani B., Glass J.D., Growdon J.H., Hamilton R.L., Harrell L.E., Head E., Honig L.S., Hulette C.M., Hyman B.T., Jicha G.A., Jin L.W., Johnson N., Karlawish J., Karydas A., Kaye J.A., Kim R., Koo E.H., Kowall N.W., Lah J.J., Levey A.I., Lieberman A.P., Lopez O.L., Mack W.J., Marson D.C., Martiniuk F., Mash D.C., Masliah E., McCormick W.C., McCurry S.M., McDavid A.N., McKee A.C., Mesulam M., Miller B.L., Miller C.A., Miller J.W., Parisi J.E., Perl D.P., Peskind E., Petersen R.C., Poon W.W., Quinn J.F., Rajbhandary R.A., Raskind M., Reisberg B., Ringman J.M., Roberson E.D., Rosenberg R.N., Sano M., Schneider L.S., Seeley W., Shelanski M.L., Slifer M.A., Smith C.D., Sonnen J.A., Spina S., Stern R.A., Tanzi R.E., Trojanowski J.Q., Troncoso J.C., Van D.V., Vinters H.V., Vonsattel J.P., Weintraub S., Welsh-Bohmer K.A., Williamson J., Woltjer R.L., Cantwell L.B., Dombroski B.A., Beekly D., Lunetta K.L., Martin E.R., Kamboh M.I., Saykin A.J., Reiman E.M., Bennett D.A., Morris J.C., Montine T.J., Goate A.M., Blacker D., Tsuang D.W., Hakonarson H., Kukull W.A., Foroud T.M., Haines J.L., Mayeux R., Pericak-Vance M.A., Farrer L.A., Schellenberg G.D. Common variants at MS4A4/MS4A6E, CD2AP. CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat. Genet. 2011, 43(5):436-441.
106. Nath S.K., Harley J.B., Lee Y.H. Polymorphisms of complement receptor 1 and interleukin-10 genes and systemic lupus erythematosus: a meta-analysis. Hum. Genet. 2005, 118:225-234.
107. Nejentsev S., Walker N., Riches D., Egholm M., Todd J.A. Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes. Science 2009, 324:387-389.
108. Nerl C., Mayeux R., O'Neill G.J. HLA-linked complement markers in Alzheimer's and Parkinson's disease: C4 variant (C4B2) a possible marker for senile dementia of the Alzheimer type. Neurology 1984, 34:310-314.
109. Ohi H., Ikezawa T., Watanabe S., Seki M., Mizutani Y., Nawa N., Hatano M. Two cases of mesangiocapillary glomerulonephritis with CR1 deficiency. Nephron 1986, 43:307.
110. Padmanabhan J., Levy M., Dickson D.W., Potter H. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons. Brain 2006, 129:3020-3034.
111. Papassotiropoulos A., Streffer J.R., Tsolaki M., Schmid S., Thal D., Nicosia F., Iakovidou V., Maddalena A., Lutjohann D., Ghebremedhin E., Hegi T., Pasch T., Traxler M., Bruhl A., Benussi L., Binetti G., Braak H., Nitsch R.M., Hock C. Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. Arch. Neurol. 2003, 60:29-35.
112. Pierce B.L., Ahsan H. Clinical assessment incorporating a personal genome. Lancet 2010, 376:869-870.
113. Pimplikar S.W. Reassessing the amyloid cascade hypothesis of Alzheimer's disease. Int. J. Biochem. Cell Biol. 2008, 41(6):1261-1268.
114. Proitsi, P., Lupton, M.K., Dudbridge, F., Tsolaki, M., Hamilton, G., Daniilidou, M., Pritchard, M., Lord, K., Martin, B.M., Craig, D., Todd, S., McGuinness, B., Hollingworth, P., Harold, D., Kloszewska, I., Soininen, H., Mecocci, P., Vellas, B., Gill, M., Lawlor, B., Rubinsztein, D.C., Brayne, C., Passmore, A.P., Williams, J., Lovestone, S., Powell, J. Alzheimer's disease and age related macular degeneration have different genetic models for complement gene variation. Neurobiol. Aging. Under review.
115. Ray S., Britschgi M., Herbert C., Takeda-Uchimura Y., Boxer A., Blennow K., Friedman L.F., Galasko D.R., Jutel M., Karydas A., Kaye J.A., Leszek J., Miller B.L., Minthon L., Quinn J.F., Rabinovici G.D., Robinson W.H., Sabbagh M.N., So Y.T., Sparks D.L., Tabaton M., Tinklenberg J., Yesavage J.A., Tibshirani R., Wyss-Coray T. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat. Med. 2007, 13:1359-1362.
116. Reiman E.M., Webster J.A., Myers A.J., Hardy J., Dunckley T., Zismann V.L., Joshipura K.D., Pearson J.V., Hu-Lince D., Huentelman M.J., Craig D.W., Coon K.D., Liang W.S., Herbert R.H., Beach T., Rohrer K.C., Zhao A.S., Leung D., Bryden L., Marlowe L., Kaleem M., Mastroeni D., Grover A., Heward C.B., Ravid R., Rogers J., Hutton M.L., Melquist S., Petersen R.C., Alexander G.E., Caselli R.J., Kukull W., Papassotiropoulos A., Stephan D.A. GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron 2007, 54:713-720.
117. Retz W., Thome J., Durany N., Harsanyi A., Retz-Junginger P., Kornhuber J., Riederer P., Rosler M. Potential genetic markers of sporadic Alzheimer's dementia. Psychiatr. Genet. 2001, 11:115-122.
118. Reynolds R., Hartnett M.E., Atkinson J.P., Giclas P.C., Rosner B., Seddon J.M. Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes. Invest. Ophthalmol. Vis. Sci. 2009, 50:5818-5827.
119. Risner M.E., Saunders A.M., Altman J.F., Ormandy G.C., Craft S., Foley I.M., Zvartau-Hind M.E., Hosford D.A., Roses A.D. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. 2006, 6:246-254.
120. Rivera A., Fisher S.A., Fritsche L.G., Keilhauer C.N., Lichtner P., Meitinger T., Weber B.H. Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum. Mol. Genet. 2005, 14:3227-3236.
121. Robman L., Baird P.N., Dimitrov P.N., Richardson A.J., Guymer R.H. C-reactive protein levels and complement factor H polymorphism interaction in age-related macular degeneration and its progression. Ophthalmology 2010, 117:1982-1988.
122. Rodriguez M.T., Calella A.M., Silva S., Munna E., Modena P., Chiesa R., Terrevazzi S., Ruggieri R.M., Palermo R., Piccoli F., Confalonieri R., Tiraboschi P., Fragiacomo C., Quadri P., Lucca U., Forloni G. Apolipoprotein E and intronic polymorphism of presenilin 1 and alpha-1-antichymotrypsin in Alzheimer's disease and vascular dementia. Dement. Geriatr. Cogn Disord. 2000, 11:239-244.
123. Rogers J., Kirby L.C., Hempelman S.R., Berry D.L., McGeer P.L., Kaszniak A.W., Zalinski J., Cofield M., Mansukhani L., Willson P. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993, 43:1609-1611.
124. Rogers J., Li R., Mastroeni D., Grover A., Leonard B., Ahern G., Cao P., Kolody H., Vedders L., Kolb W.P., Sabbagh M. Peripheral clearance of amyloid beta peptide by complement C3-dependent adherence to erythrocytes. Neurobiol. Aging 2006, 27:1733-1739.
125. Rosenmann H., Meiner Z., Kahana E., Aladjem Z., Friedman G., Ben-Yehuda A., Grenader T., Wertman E., Abramsky O. A polymorphism in the complement component C1r is not associated with sporadic Alzheimer's disease. Neurosci. Lett. 2003, 336:101-104.
126. Rozek W., Ricardo-Dukelow M., Holloway S., Gendelman H.E., Wojna V., Melendez L.M., Ciborowski P. Cerebrospinal fluid proteomic profiling of HIV-1-infected patients with cognitive impairment. J. Proteome Res. 2007, 6:4189-4199.
127. Sasaki K., Doh-ura K., Ironside J.W., Iwaki T. Increased clusterin (apolipoprotein J) expression in human and mouse brains infected with transmissible spongiform encephalopathies. Acta Neuropathol. 2002, 103:199-208.
128. Scacchi R., Gambina G., Ruggeri M., Martini M.C., Ferrari G., Silvestri M., Schiavon R., Corbo R.M. Plasma levels of apolipoprotein E and genetic markers in elderly patients with Alzheimer's disease. Neurosci. Lett. 1999, 259:33-36.
129. Schjeide B.M., Schnack C., Lambert J.C., Lill C.M., Kirchheiner J., Tumani H., Otto M., Tanzi R.E., Lehrach H., Amouyel P., von Arnim C.A., Bertram L. The role of clusterin, complement receptor 1, and phosphatidylinositol binding clathrin assembly protein in Alzheimer disease risk and cerebrospinal fluid biomarker levels. Arch. Gen. Psychiatry 2011, 68:207-213.
130. Scholl H.P., Charbel I.P., Walier M., Janzer S., Pollok-Kopp B., Borncke F., Fritsche L.G., Chong N.V., Fimmers R., Wienker T., Holz F.G., Weber B.H., Oppermann M. Systemic complement activation in age-related macular degeneration. PLoS One 2008, 3:e2593.
131. Schrijvers E.M., Koudstaal P.J., Hofman A., Breteler M.M. Plasma clusterin and the risk of Alzheimer disease. JAMA 2011, 305:1322-1326.
132. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001, 81:741-766.
133. Selkoe D.J., Podlisny M.B. Deciphering the genetic basis of Alzheimer's disease. Annu. Rev. Genomics Hum. Genet. 2002, 3:67-99.
134. Seshadri S., Fitzpatrick A.L., Ikram M.A., DeStefano A.L., Gudnason V., Boada M., Bis J.C., Smith A.V., Carassquillo M.M., Lambert J.C., Harold D., Schrijvers E.M., Ramirez-Lorca R., Debette S., Longstreth W.T., Janssens A.C., Pankratz V.S., Dartigues J.F., Hollingworth P., Aspelund T., Hernandez I., Beiser A., Kuller L.H., Koudstaal P.J., Dickson D.W., Tzourio C., Abraham R., Antunez C., Du Y., Rotter J.I., Aulchenko Y.S., Harris T.B., Petersen R.C., Berr C., Owen M.J., Lopez-Arrieta J., Varadarajan B.N., Becker J.T., Rivadeneira F., Nalls M.A., Graff-Radford N.R., Campion D., Auerbach S., Rice K., Hofman A., Jonsson P.V., Schmidt H., Lathrop M., Mosley T.H., Au R., Psaty B.M., Uitterlinden A.G., Farrer L.A., Lumley T., Ruiz A., Williams J., Amouyel P., Younkin S.G., Wolf P.A., Launer L.J., Lopez O.L., van Duijn C.M., Breteler M.M. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 2010, 303:1832-1840.
135. Silbert L.C., Quinn J.F., Moore M.M., Corbridge E., Ball M.J., Murdoch G., Sexton G., Kaye J.A. Changes in premorbid brain volume predict Alzheimer's disease pathology. Neurology 2003, 61:487-492.
136. Simmons A., Westman E., Muehlboeck S., Mecocci P., Vellas B., Tsolaki M., Kloszewska I., Wahlund L.O., Soininen H., Lovestone S., Evans A., Spenger C. The AddNeuroMed framework for multi-centre MRI assessment of Alzheimer's disease: experience from the first 24 months. Int. J. Geriatr. Psychiatry 2011, 26:75-82.
137. Sivaprasad S., Adewoyin T., Bailey T.A., Dandekar S.S., Jenkins S., Webster A.R., Chong N.V. Estimation of systemic complement C3 activity in age-related macular degeneration. Arch. Ophthalmol. 2007, 125:515-519.
138. Smyth M.D., Cribbs D.H., Tenner A.J., Shankle W.R., Dick M., Kesslak J.P., Cotman C.W. Decreased levels of C1q in cerebrospinal fluid of living Alzheimer patients correlate with disease state. Neurobiol. Aging 1994, 15:609-614.
139. Soares H.D., Chen Y., Sabbagh M., Roher A., Schrijvers E., Breteler M. Identifying early markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels. Ann. N.Y. Acad. Sci. 2009, 1180:56-67.
140. Spencer K.L., Olson L.M., Schnetz-Boutaud N., Gallins P., Agarwal A., Iannaccone A., Kritchevsky S.B., Garcia M., Nalls M.A., Newman A.B., Scott W.K., Pericak-Vance M.A., Haines J.L. Using genetic variation and environmental risk factor data to identify individuals at high risk for age-related macular degeneration. PLoS One 2011, 6:e17784.
141. Stewart W.F., Kawas C., Corrada M., Metter E.J. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997, 48:626-632.
142. Tacnet-Delorme P., Chevallier S., Arlaud G.J. Beta-amyloid fibrils activate the C1 complex of complement under physiological conditions: evidence for a binding site for A beta on the C1q globular regions. J. Immunol. 2001, 167:6374-6381.
143. Talbot C., Houlden H., Craddock N., Crook R., Hutton M., Lendon C., Prihar G., Morris J.C., Hardy J., Goate A. Polymorphism in AACT gene may lower age of onset of Alzheimer's disease. Neuroreport 1996, 7:534-536.
144. Tang N.P., Zhou B., Wang B., Yu R.B. HTRA1 promoter polymorphism and risk of age-related macular degeneration: a meta-analysis. Ann. Epidemiol. 2009, 19:740-745.
145. Thambisetty M., Hye A., Foy C., Daly E., Glover A., Cooper A., Simmons A., Murphy D., Lovestone S. Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer's disease. J. Neurol. 2008, 255:1712-1720.
146. Thambisetty M., Simmons A., Velayudhan L., Hye A., Campbell J., Zhang Y., Wahlund L.O., Westman E., Kinsey A., Guntert A., Proitsi P., Powell J., Causevic M., Killick R., Lunnon K., Lynham S., Broadstock M., Choudhry F., Howlett D.R., Williams R.J., Sharp S.I., Mitchelmore C., Tunnard C., Leung R., Foy C., O'Brien D., Breen G., Furney S.J., Ward M., Kloszewska I., Mecocci P., Soininen H., Tsolaki M., Vellas B., Hodges A., Murphy D.G., Parkins S., Richardson J.C., Resnick S.M., Ferrucci L., Wong D.F., Zhou Y., Muehlboeck S., Evans A., Francis P.T., Spenger C., Lovestone S. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch. Gen. Psychiatry 2010, 67:739-748.
147. Turunen M., Vepsalainen S., Makinen P., Helisalmi S., Haapasalo A., Soininen H., Hiltunen M. No association between high temperature requirement 1 (HTRA1) gene polymorphisms and Alzheimer's disease. Neurobiol. Aging 2011, 32:547-549.
148. van Oijen M., de Maat M.P., Kardys I., de Jong F.J., Hofman A., Koudstaal P.J., Witteman J.C., Breteler M.M. Polymorphisms and haplotypes in the C-reactive protein gene and risk of dementia. Neurobiol. Aging 2007, 28:1361-1366.
149. Weiner M.W. Imaging and biomarkers will be used for detection and monitoring progression of early Alzheimer's disease. J. Nutr. Health Aging 2009, 13:332.
150. Wheeler D.A., Srinivasan M., Egholm M., Shen Y., Chen L., McGuire A., He W., Chen Y.J., Makhijani V., Roth G.T., Gomes X., Tartaro K., Niazi F., Turcotte C.L., Irzyk G.P., Lupski J.R., Chinault C., Song X.Z., Liu Y., Yuan Y., Nazareth L., Qin X., Muzny D.M., Margulies M., Weinstock G.M., Gibbs R.A., Rothberg J.M. The complete genome of an individual by massively parallel DNA sequencing. Nature 2008, 452:872-876.
151. Wilson M.R., Roeth P.J., Easterbrook-Smith S.B. Clusterin enhances the formation of insoluble immune complexes. Biochem. Biophys. Res. Commun. 1991, 177:985-990.
152. Yang Z., Camp N.J., Sun H., Tong Z., Gibbs D., Cameron D.J., Chen H., Zhao Y., Pearson E., Li X., Chien J., Dewan A., Harmon J., Bernstein P.S., Shridhar V., Zabriskie N.A., Hoh J., Howes K., Zhang K. A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration. Science 2006, 314:992-993.
153. Yasojima K., Schwab C., McGeer E.G., McGeer P.L. Up-regulated production and activation of the complement system in Alzheimer's disease brain. Am. J. Pathol. 1999, 154:927-936.
154. Yates J.R., Sepp T., Matharu B.K., Khan J.C., Thurlby D.A., Shahid H., Clayton D.G., Hayward C., Morgan J., Wright A.F., Armbrecht A.M., Dhillon B., Deary I.J., Redmond E., Bird A.C., Moore A.T. Complement C3 variant and the risk of age-related macular degeneration. N. Engl. J. Med. 2007, 357:553-561.
155. Yerbury J.J., Poon S., Meehan S., Thompson B., Kumita J.R., Dobson C.M., Wilson M.R. The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures. FASEB J. 2007, 21:2312-2322.
156. Zanjani H., Finch C.E., Kemper C., Atkinson J., McKeel D., Morris J.C., Price J.L. Complement activation in very early Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2005, 19:55-66.
157. Zetterberg M., Landgren S., Andersson M.E., Palmer M.S., Gustafson D.R., Skoog I., Minthon L., Thelle D.S., Wallin A., Bogdanovic N., Andreasen N., Blennow K., Zetterberg H. Association of complement factor H Y402H gene polymorphism with Alzheimer's disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2008, 147B:720-726.
158. Zhang Q., Yu J.T., Zhu Q.X., Zhang W., Wu Z.C., Miao D., Tan L. Complement receptor 1 polymorphisms and risk of late-onset Alzheimer's disease. Brain Res. 2010, 1348:216-221.